← Back to Search

Sevoflurane for Neurocognitive Effects Related to Pain and Anesthesia (SENS Trial)

Phase 1
Recruiting
Led By Keith M Vogt, MD, PhD
Research Sponsored by Keith M. Vogt, MD, PhD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Have normal hearing and memory
Adults, age 18-59, who are native English speakers with at least a high school education
Timeline
Screening 3 weeks
Treatment Varies
Follow Up visit 2: 24-hrs post-learning experiment
Awards & highlights

SENS Trial Summary

This trial will use MRI scans to study how pain affects memory and physiology, using a low dose of sevoflurane. 2 visits are required, no long-term follow up.

Who is the study for?
This trial is for healthy adults aged 18-59 with normal hearing, memory, and body weight. Participants must be native English speakers with at least a high school education, not pregnant, without chronic diseases or severe medical conditions like heart disease or seizures, and free from drug use including marijuana and heavy alcohol consumption.Check my eligibility
What is being tested?
The study tests how acute pain affects long-term memory and physiological responses with/without low-dose sevoflurane anesthesia. It involves two visits with no long-term follow-up using functional MRI to examine brain activity related to these effects.See study design
What are the potential side effects?
While the side effects are not explicitly listed in the provided information, common side effects of sevoflurane may include nausea, vomiting, throat irritation, coughing or muscle twitching during recovery from anesthesia.

SENS Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My hearing and memory are normal.
Select...
I am between 18 and 59 years old, speak English natively, and have finished high school.

SENS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~visit 2: 24-hrs post-learning experiment
This trial's timeline: 3 weeks for screening, Varies for treatment, and visit 2: 24-hrs post-learning experiment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Functional connectivity
functional magnetic resonance imaging activation in response to experimental tasks
Secondary outcome measures
Explicit memory performance

SENS Trial Design

1Treatment groups
Experimental Treatment
Group I: Sevoflurane+PainExperimental Treatment2 Interventions
Single-arm study. All subjects receive sevoflurane and painful electric nerve stimulation, as described in the interventions.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Peripheral Nerve Stimulation
2016
Completed Phase 1
~1380
Sevoflurane
2016
Completed Phase 4
~1260

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Keith M. Vogt, MD, PhDLead Sponsor
3 Previous Clinical Trials
190 Total Patients Enrolled
National Institute of General Medical Sciences (NIGMS)NIH
269 Previous Clinical Trials
247,052 Total Patients Enrolled
Keith M Vogt, MD, PhDPrincipal InvestigatorUniversity of Pittsburgh
3 Previous Clinical Trials
212 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research open to participants who are over twenty years old?

"The study is open to those aged 18 or above and younger than 59."

Answered by AI

Who qualifies to take part in this scientific exploration?

"For this medical trial to be successful, 60 individuals that meet the criteria of being 18-59 years old and having amnesia must enroll."

Answered by AI

Are recruitment efforts still underway for this experiment?

"According to the clinicaltrials.gov page, this investigation is presently in search of participants since it was first published on December 1st 2023 and amended most recently on September 17th2023."

Answered by AI

How great is the full cohort size of this medical experiment?

"Affirmative, clinicaltrials.gov indicates that this research is actively recruiting participants. The original post was published on December 1st 2023 and it has since been updated on September 17th of the same year. Sixty volunteers are needed to take part at a single enrolment site."

Answered by AI

Has the FDA sanctioned Sevoflurane+Pain as a safe and effective treatment?

"Due to the limited data present, our team at Power has judged Sevoflurane+Pain's safety on a scale from 1 to 3 as just 1. This is because this medical trial is currently in its first phase of analysis and there have been few indications concerning the efficacy or security of this treatment."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Sevoflurane's Effect on Neurocognition Study
Keith M. Vogt, MD, PhD 2024. "Sevoflurane's Effect on Neurocognition Study". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06044740.
~40 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top